在HER2-阳性转移性乳腺癌中新获批准和新兴的药物
Stephanie L Graff1, Fengting Yan2, Yara Abdou3
1Ambulatory Patient Center, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University, Rhode Island Hospital, Providence, RI.
Clinical breast cancer
|July 5, 2023
概括
对HER2阳性转移性乳腺癌 (mBC) 的治疗环境正在迅速发展,新的向疗法和抗体-药物联合体 (ADC) 正在迅速发展. 这些进展为HER2+mBC患者提供了更好的结果和更个性化的治疗选择.
科学领域:
- 在瘤学瘤学.
- 医学治疗学 医学治疗学
- 临床研究 临床研究
背景情况:
- 人类表皮生长因子受体2-阳性乳腺癌 (HER2+BC) 占美国乳腺癌病例的15-20%.
- HER2+转移性乳腺癌 (mBC) 是一种侵略性的亚型,需要专门的治疗策略.
- 在过去的十年中,有针对性的疗法显著改善了HER2+mBC患者的治疗结果.
研究的目的:
- 审查 HER2+ 转移性乳腺癌的当前和新兴治疗方案.
- 讨论在一线,二线和以后的设置中不断变化的治疗范式.
- 突出影响治疗决策的因素和HER2+mBC治疗的未来方向.
主要方法:
- 临床试验和治疗在HER2+mBC中的进展的文献综述.
- 对标准护理 (SOC) 治疗方法和新药的分析,包括抗体药物联合体 (ADC) 和氨酸激酶抑制剂 (TKI).
- 讨论正在进行的研究和正在对HER2+mBC进行评估的新药类.
主要成果:
- 对HER2+mBC的第一线SOC仍然是针对HER2的单克隆抗体加上一个分类基因.
- 在二线设置中,Trastuzumab deruxtecan比trastuzumab emtansine更受青.
- 多种治疗选择,包括TKI,mAbs和ADC,可用于第三线和超越治疗.
结论:
- 治疗HER2+mBC的特点是不断扩大治疗选择的范围.
- 治疗决策应考虑转移的位置,先前的治疗方法,生物标志物和不良事件管理.
- 目前正在进行的临床试验和新型药物类别有望进一步改善患者的治疗结果,并为HER2+mBC提供个性化的护理.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
205
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
205
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
249
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
249
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


